

Supplementary material

Tajstra M, Wilczek K, Witkowski A, et al. Management of patients with acute myocardial infarction treated between 2019–2022 with 12-month follow-up: Data from comprehensive all-comers administrative database covering a whole population of Poland. Pol Heart J. 2025.

Please note that the journal is not responsible for the scientific accuracy or functionality of any supplementary material submitted by the authors. Any queries (except missing content) should be directed to the corresponding author of the article.

Table S1. Baseline characteristics, in-hospital outcomes of the patients with acute myocardial infarction

Baseline characteristics	n = 292 284
Variable	
Age, years, mean (SD)	68.1 (11.2)
Male sex, n (%)	188 429 (64.5)
Diabetes, n (%)	88 005 (30.1)
Hyperlipidemia, n (%)	49 147 (16.8)
Atrial fibrillation, n (%)	34 327 (11.7)
Arterial hypertension, n (%)	201 595 (69)
Chronic coronary syndrome, n (%)	123 724 (42.3)
Previous coronary angiography, n (%)	58 409 (20)
Previous stroke, n (%)	9451 (3.2)
Previous percutaneous coronary intervention, n (%)	44 708 (15.3)
Previous coronary artery bypass grafting, n (%)	3348 (1.1)
Chronic kidney disease, n (%)	19 927 (6.8)
Dialysis, n (%)	3606 (1.2)
Peripheral artery disease, n (%)	2814 (1.0)
Chronic obstructive pulmonary disease, n (%)	27 698 (9.5)
In-hospital treatment and outcomes	n = 292 284
Coronary angiography, n (%)	268 581 (92)
FFR assessment, n (%)	10 717 (3.7)
Percutaneous coronary intervention, n (%)	222 668 (76.2)

IVUS, n (%)	15 879 (5.4)
Coronary artery bypass grafting, n (%)	9914 (3.4)
Blood transfusion, n (%)	20 512 (7)
Cardiogenic shock, n (%)	7064 (2.4)
Intensive care unit stay, n (%)	14 746 (5)
All-cause death, n (%)	25 666 (8.8)
Medical therapy prescribed at discharge, n (%)	
Dual antiplatelet therapy	250 620 (94)
Statins	239 956 (90)
Beta blockers	194 631 (73)
ACEI/ARB	210 628 (79)
MRA	72 076 (24.6)
SGLT2 inhibitors	25 851 (8.8)
Loop diuretic	78 778 (26.9)
OAC	46 708 (16)
DOAC	42 149 (14.4)
VKA	4559 (1.6)

Abbreviations: ACEI, angiotensin-converting enzyme inhibitors; ARB, angiotensin receptor blockers; DOAC, direct oral anticoagulants; FFR, fractional flow reserve; IVUS, intravascular ultrasonography; MRA, mineralocorticoid receptor antagonist; OAC, oral anticoagulants; SGLT2, sodium-glucose cotransporter-2; VKA, vitamin K antagonists

Table S2. 12-month data of the patients with acute myocardial infarction

12-month data	n = 292 284
Coronary angiography, n (%)	61 814 (21.1)
Percutaneous coronary intervention, n (%)	46 002 (15.7)
Coronary artery bypass grafting, n (%)	6382 (2.2)
Hospitalization due to cardiovascular reason, n (%)	131 678 (45.1)
Cardiac rehabilitation, n (%)	89 035 (30.5)
KOS-zawał, n (%)	58 936 (20.2)
Myocardial infarction, n (%)	16549 (5.7)
Stroke, n (%)	3579 (1.2)
All-cause death, n (%)	52583 (18)